Nerve testing devices maker NeuroMetrix (NURO - Free Report) will showcase its latest test, the NC-stat DPNCheck, at the annual meeting of The Endocrine Society (“ENDO 2011”) slated to be held in Boston from June 4 to June 6, 2011. The product was successfully previewed, in April 2011, at the Annual Meeting of the American Association of Clinical Endocrinologists (“AACE”) in San Diego, California.
The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”). Visitors at NeuroMetrix’s booth at the ENDO 2011 can learn about the product, view a live demonstration, meet with the company representatives and inquire about trial.
DPN, a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. Currently, there is a lack of standardized test for DPN at the point-of-care, triggering a large unmet need.
NC-stat DPNCheck is a modified version of NeuroMetrix’s popular NC-stat device for detecting DPN. This new point-of-care device is expected to help in the early detection, confirmation, and monitoring of DPN in a cost-effective manner, thereby enabling the company to address the need for a widely available, standardized test for DPN. NeuroMetrix plans to launch NC-stat DPNCheck at the annual conference of the American Diabetes Association (“ADA”) in second-half 2011.
NeuroMetrix develops and markets devices that help physicians detect and treat diseases and peripheral nerve injuries, and offer regional anesthesia and pain control. The company’s principal products are ADVANCE and NC-stat devices for nerve conduction study (“NCS”). NeuroMetrix competes with Medtronic (MDT - Free Report) among others.
NeuroMetrix, in January 2011, modified its operational focus in favor of diabetes, in particular the diagnosis and monitoring of DPN. Moreover, the company, in March 2011, established a scientific advisory board for its new DPN test. The board consists of eminent international experts who will work closely with the company for improving detection, monitoring and management of DPN.